Optimizing (neo)adjuvant treatment of HER2-positive breast cancer

Optimizing (neo)adjuvant treatment of HER2-positive breast cancer

The development of human epidermal growth factor 2 (HER2)-directed therapy has resulted in significant improvement in outcomes for patients with early-stage HER2-overexpressing (HER2+) breast cancer. In recent years, newer HER2-directed agents and novel treatment strategies have been developed with...

Full description

Bibliographic Details
Main Authors:	Reva K. Basho, Heather L. McArthur
Format:	Article
Language:	English
Published:	SAGE Publishing 2018-05-01
Series:	Therapeutic Advances in Medical Oncology
Online Access:	https://doi.org/10.1177/1758835918775697

Similar Items

Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
by: Advani P, et al.
Published: (2015-09-01)

Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial
by: Serena Di Cosimo, et al.
Published: (2020-10-01)

Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer
by: N. Harbeck
Published: (2021-04-01)

Adjuvant application of trastuzumab in HER2 positive breast cancer and impact on time to relapse
by: Dukić Nikolina, et al.
Published: (2020-01-01)

What is the optimal neo-adjuvant treatment for liver metastasis?
by: Sigurdis Haraldsdottir, et al.
Published: (2013-07-01)

Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials
by: Soares Francisco V, et al.
Published: (2007-08-01)

Her2 Expression and Response of Breast Cancer to Adjuvant Chemotherapy
by: Hegmane Alinta, et al.
Published: (2008-01-01)

Treatment of HER2 positive breast cancer patients
by: Erika Matos
Published: (2012-03-01)

Neo-adjuvant chemotherapy in luminal, node positive breast cancer: characteristics, treatment, and oncological outcomes. A single center’s experience
by: E. Barbieri, et al.
Published: (2021-04-01)

Clinical impact of interruption in adjuvant Trastuzumab therapy in patients with operable HER-2 positive breast cancer
by: Sagar Sardesai, et al.
Published: (2020-11-01)

Role of neo-adjuvant hormonal therapy in the treatment of breast cancer: a review of clinical trials
by: Catherine Abrial, et al.
Published: (2009-07-01)

Freund's vaccine adjuvant promotes Her2/Neu breast cancer
by: Woditschka Stephan, et al.
Published: (2009-01-01)

De-escalation of adjuvant chemotherapy for HER2 negative breast cancer
by: Dr Alicia FC Okines, et al.
Published: (2021-06-01)

Target therapy in treatment of HER2-positive breast cancer
by: A. S. Belokhvostova, et al.
Published: (2016-02-01)

The Changing Paradigm for the Treatment of HER2-Positive Breast Cancer
by: Aena Patel, et al.
Published: (2020-07-01)

Role of pertuzumab in the treatment of HER2-positive breast cancer
by: Hubalek M, et al.
Published: (2012-05-01)

New developments in the treatment of HER2-positive breast cancer
by: Nahta R
Published: (2012-05-01)

Endocrine Therapy Plus Anti-HER2 Therapy as Adjuvant Systemic Therapy for Luminal HER2-Positive Breast Cancer: An Analysis of the National Cancer Database
by: Zeina A Nahleh, et al.
Published: (2020-07-01)

Genetic Variability of Antioxidative Mechanisms and Cardiotoxicity after Adjuvant Radiotherapy in HER2-Positive Breast Cancer Patients
by: Tanja Marinko, et al.
Published: (2020-01-01)

Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines
by: Anne Julienne Genuino, et al.
Published: (2019-11-01)

Cost-effectiveness of adjuvant paclitaxel and trastuzumab for early-stage node-negative, HER2-positive breast cancer.
by: Ali Hajjar, et al.
Published: (2019-01-01)

Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: a meta-analysis of published randomized controlled trials.
by: Wenjin Yin, et al.
Published: (2011-01-01)

Adjuvant treatment for triple negative breast cancer with residual tumor after neo-adjuvant chemotherapy. A single institutional retrospective analysis
by: Nadia Bianco, et al.
Published: (2021-10-01)

Practical consensus recommendations for neo-adjuvant chemotherapy in triple negative breast cancer
by: G S Bhattacharyya, et al.
Published: (2018-01-01)

Morphological Estimation of Cellularity on Neo-Adjuvant Treated Breast Cancer Histological Images
by: Mauricio Alberto Ortega-Ruiz, et al.
Published: (2020-09-01)

Tumor response to neo-adjuvant chemotherapy for breast cancer: dependent on texture features
by: Min-Hsuan Chen, et al.
Published: (2016)

Invasive micropapillary carcinoma of the breast overexpresses MUC4 and is associated with poor outcome to adjuvant trastuzumab in HER2-positive breast cancer
by: María F. Mercogliano, et al.
Published: (2017-12-01)

Cancer Vaccines, Treatment of the Future: With Emphasis on HER2-Positive Breast Cancer
by: Sandeep Pallerla, et al.
Published: (2021-01-01)

Ribociclib for the treatment of hormone-positive HER2-negative breast cancer
by: I. P. Ganshina, et al.
Published: (2019-06-01)

Potential of afatinib in the treatment of patients with HER2-positive breast cancer
by: Geuna E, et al.
Published: (2012-08-01)

Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer
by: Oostra DR, et al.
Published: (2014-07-01)

The expanding role of pertuzumab in the treatment of HER2-positive breast cancer
by: Moya-Horno I, et al.
Published: (2015-05-01)

Current neoadjuvant treatment options for HER2 positive breast cancer
by: Abdel-Razeq H, et al.
Published: (2011-08-01)

Somatic Mutations in HER2 and Implications for Current Treatment Paradigms in HER2-Positive Breast Cancer
by: Maria Gaibar, et al.
Published: (2020-01-01)

5-year follow-up of the safety, tolerability and efficacy of subcutaneous trastuzumab for the adjuvant treatment of HER2-positive early breast cancer. Results from the SafeHER Phase III trial
by: J. Gligorov, et al.
Published: (2021-04-01)

Prior Adjuvant Tamoxifen Treatment in Breast Cancer Is Linked to Increased AIB1 and HER2 Expression in Metachronous Contralateral Breast Cancer.
by: Sara Alkner, et al.
Published: (2016-01-01)

Trastuzumab emtansine of the treatment of HER2-positive breast cancer with brain metatases
by: L. Yu. Vladimirova, et al.
Published: (2020-12-01)

Long-term trastuzumab treatment in HER2 positive metastatic breast cancer
by: M. Calamac, et al.
Published: (2021-04-01)

Partnering Teams to Optimize the Care of Patients With HER2-Positive Breast Cancer∗
by: Erica L. Mayer, MD, MPH
Published: (2020-06-01)

Aspectos clínico-econômicos da quimioterapia adjuvante no câncer de mama HER-2 positivo Clinical and economic issues in adjuvant chemotherapy for HER-2 positive breast cancer
by: Sandro José Martins, et al.
Published: (2008-12-01)